Key Aspirin Exacerbated Respiratory Disease Market Players:
- Sanofi
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Regeneron Pharmaceuticals
- GlaxoSmithKline (GSK)
- AstraZeneca
- Novartis
- Teva Pharmaceuticals
- Amgen
- CSL Limited
- Mitsubishi Tanabe Pharma
- Hanmi Pharmaceutical
- Lupin Limited
- Cipla
- BioMérieux
- Glenmark Pharmaceuticals
- Dr. Reddy’s Laboratories
- Chugai Pharmaceutical (Roche Group)
- Biocon Biologics
- Pharmaniaga Berhad
- Takeda Pharmaceutical
- Torrent Pharmaceuticals
The global aspirin exacerbated respiratory disease market is dominated by multinational players such as Sanofi, Regeneron, and GSK, with a market share of more than 34.4%. These players are heavily investing in biologic treatments like anti-IL-4, IL-5, and IL-13 monoclonal antibodies to treat complicated AERD phenotypes. Strategic partnerships between Sanofi and Regeneron for Dupixent have surged the aspirin exacerbated respiratory disease market growth. Meanwhile, companies in India, Japan, and South Korea are using biosimilars, generics, and local manufacturing joint ventures to compete on price and availability. Diagnostic innovation from companies such as bioMérieux is improving patient phenotyping and informing personalized AERD treatment regimens.
The top 20 cohort of such key players include:
